ALDX

1.485

3.57% -0.055

Pre-mercato: 1.59 0.105 +7.07%

Aldeyra Therapeutics Inc (ALDX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.54

Aprire:

$1.52

Volume 24 ore:

547.97K

Relative Volume:

0.41

Capitalizzazione di mercato:

$89.58M

Reddito:

Utile/perdita netta:

$-27.37M

Rapporto P/E:

-3.2623

EPS:

-0.4552

Flusso di cassa netto:

$-25.99M

1 W Prestazione:

-2.30%

1M Prestazione:

-6.01%

6M Prestazione:

-72.80%

1 anno Prestazione:

-74.66%

Intervallo 1D:

$1.48

$1.56

Intervallo di 1 settimana:

$1.4601

$1.581

Portata 52W:

$1.07

$5.93

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Nome

Aldeyra Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (605)

Telefono

781-761-4904

Indirizzo

131 HARTWELL AVENUE, LEXINGTON, MA

Dipendente

Cinguettio

@aldeyraaldx

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

ALDX's Discussions on Twitter

Compare ALDX vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALDX Aldeyra Therapeutics Inc	1.485	90.49M	0	-27.37M	-25.99M	-0.4552
VRTX Vertex Pharmaceuticals Inc	541.69	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	794.19	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,023.21	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.99	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.88	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-18	Downgrade	H.C. Wainwright	Buy → Neutral
2024-04-03	Aggiornamento	Oppenheimer	Perform → Outperform
2024-04-02	Ripresa	H.C. Wainwright	Buy
2022-04-27	Ripresa	H.C. Wainwright	Buy
2021-02-08	Iniziato	H.C. Wainwright	Buy
2020-12-16	Iniziato	Berenberg	Buy
2020-10-30	Iniziato	Jefferies	Buy
2020-10-16	Iniziato	BTIG Research	Buy
2020-09-22	Iniziato	Alliance Global Partners	Buy
2020-05-12	Iniziato	Oppenheimer	Outperform
2018-12-04	Iniziato	Citigroup	Buy
2018-09-26	Reiterato	Cantor Fitzgerald	Overweight
2018-09-13	Iniziato	Janney	Buy
2018-01-26	Iniziato	Seaport Global Securities	Buy
2016-09-26	Iniziato	H.C. Wainwright	Buy
2016-07-01	Iniziato	Stifel	Buy
2015-07-01	Iniziato	Canaccord Genuity	Buy
2015-03-25	Iniziato	Chardan Capital Markets	Buy
2015-03-20	Reiterato	H.C. Wainwright	Buy
2014-11-18	Iniziato	H.C. Wainwright	Buy
2014-06-19	Iniziato	Aegis Capital	Buy

Mostra tutto

Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie

Aug 19, 2026

Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat

Aug 19, 2026

Aug 18, 2026

AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus

Aug 18, 2026

HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat

Aug 18, 2026

Aug 17, 2026

H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo

Aug 17, 2026

Aug 16, 2026

Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - Vinanet

Aug 16, 2026

Aug 15, 2026

Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 12, 2026

Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan

Aug 12, 2026

ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 12, 2026

Aug 11, 2026

ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Aug 11, 2026

Aug 09, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 09, 2026

Aug 07, 2026